News
Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body
Nature · By Heidi Ledford ·
The Brief
- A novel CRISPR therapy is poised to gain its first FDA approval for altering genes inside the body.
- Earlier CRISPR treatments require removing a participant's cells, a complex and costly approach.
Why it matters
An in-body approach would avoid removing and reinfusing a patient's cells, which the source describes as complex and costly in earlier CRISPR treatments.
Who’s affected
- patients with genetic diseases
- biomedical researchers and clinicians working on gene editing
Nature, Published online: 12 November 2026; doi:10.1038/d41586-026-03705-9 Earlier CRISPR treatments require removal of a participant’s cells, a complex and costly approach.